Beyond PARP - Next Generation DDR Therapeutics Q3 2017
Safe Harbor Statement Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “plan”, “predict”, “expect,” “estimate,” “anticipate,” “intend,” “goal,” “strategy,” “believe,” and similar expressions and variations thereof. Forward-looking statements may include statements regarding the Company’s business strategy, potential growth opportunities, clinical development activities, the timing and results of preclinical research, clinical trials and potential regulatory approval and commercialization of product candidates. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company cannot guarantee future events, results, actions, levels of activity, performance or achievements. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in documents the Company has filed with the SEC. These forward-looking statements speak only as of the date of this presentation and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof. Certain information contained in this presentation may be derived from information provided by industry sources. The Company believes such information is accurate and that the sources from which it has been obtained are reliable. However, the Company cannot guarantee the accuracy of, and has not independently verified, such information. Trademarks: The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products. 2 SIERRA ONCOLOGY
Sierra Oncology A clinical-stage drug development company advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer. NASDAQ: SRRA Headquarters: Vancouver, BC We are an ambitious oncology drug Shares (06/30/17) : development company oriented to 52.3M outstanding registration and commercialization. 60.0M fully diluted Cash on hand (06/30/17) : $116.7M We have a highly experienced management team with a proven track record in oncology drug development. 3 SIERRA ONCOLOGY
Expanding Beyond PARP The DNA Damage Response (DDR) network is an emerging biological target space for cancer, validated by the clinical success of PARP inhibitors. Our pipeline assets are potent, highly selective, oral kinase inhibitors against Chk1 (SRA737) and Cdc7 (SRA141), with excellent drug-like properties. Lead program SRA737 targets Chk1, a clinically-validated target with potential for synthetic lethality in genetically-defined backgrounds. SRA737 is in two active Phase 1 clinical studies employing a novel prospective patient enrichment strategy. Cash runway to mid-2019 delivers multiple data readouts, with preliminary data anticipated in early 2018. 4 SIERRA ONCOLOGY
Our Pipeline of ‘Next Generation’ DDR Therapeutics Preclinical Phase 1 Phase 2 Phase 1 SRA737 Monotherapy Chk1 Advanced solid tumors, Currently enrolling Targeting Phase 1 Checkpoint kinase 1 Low-Dose Gemcitabine Combination Advanced solid tumors, Currently enrolling SRA141 Cdc7 Plan to file IND H2 2017 Targeting Cell division cycle 7 5 SIERRA ONCOLOGY
DDR Advisory Committee – Leading DDR Experts Represented by leading experts in DDR biology, chemistry and medicine; Providing advice on our DDR oriented development programs with a focus on maximizing the potential clinical and commercial deployment of our drug candidates. • Eric J. Brown, PhD Associate Professor of Cancer Biology at the Perelman School of Medicine of the University of Pennsylvania. • Karlene Cimprich, PhD Vice Chair and Professor of Chemical and Systems Biology at the Stanford University School of Medicine. • Alan D. D'Andrea, MD Fuller-American Cancer Society Professor of Radiation Oncology at Harvard Medical School and the Director of the Center for DNA Damage and Repair at the Dana-Farber Cancer Institute. • Alan R. Eastman, PhD Professor at the Geisel School of Medicine at Dartmouth and the founding Director of the Molecular Therapeutics Research Program of the Norris Cotton Cancer Center at Dartmouth. • Michelle D. Garrett, PhD Professor of Cancer Therapeutics in the School of Biosciences at the University of Kent and Visiting Professor of Cancer Therapeutics at the Institute of Cancer Research, London, UK. • Thomas Helleday, PhD The Torsten and Ragnar Söderberg Professor of Translational Medicine and Chemical Biology at Karolinska Institutet, Stockholm, Sweden. • Leonard Post, PhD Chief Scientific Officer of Vivace Therapeutics; former CSO of BioMarin Pharmaceuticals. 6 SIERRA ONCOLOGY
Beyond PARP: Our DNA Damage Response (DDR) Program 7 SIERRA ONCOLOGY
DDR Network: Detects DNA Damage, Pauses the Cell Cycle and Repairs DNA DDR pathways repair DNA damage damaged DNA detected Stalled Single strand Double strand replication forks breaks breaks DDR pathways Cdc7 trigger cell cycle G1 / S checkpoints Checkpoint ATM ATR Cell Cycle PARP Chk1 G2 / M S Phase Checkpoint Homologous Checkpoint Base Excision Recombination Repair Chk1 Repair (BER) (HRR) Chk1 Cdc7 8 SIERRA ONCOLOGY
SRA737 Targeting Chk1 9 SIERRA ONCOLOGY
Chk1 is an Attractive Emerging Therapeutic Target in Cancer Chk1 plays an important dual role: 2) in the repair of DNA double strand breaks 1) as a key regulator of the cell cycle Chk1 mediates DNA repair G1/S-defective cancer cells are reliant on remaining Chk1-regulated checkpoints Defective G1 / S Checkpoint Stalled Single strand Double strand replication forks breaks breaks Cancer Cell ATM ATR Cycle G2 / M PARP Chk1 S Phase Checkpoint Checkpoint Homologous Base Excision Chk1 Recombination Repair Chk1 Repair (BER) (HRR) 10 SIERRA ONCOLOGY
SRA737 – Potential Best-In-Class Chk1 Inhibitor Clinically Validated Target • Clinical efficacy reported as monotherapy with prexasertib (LY2606368). • Gemcitabine combination efficacy reported with GDC-0575. Superior Drug Profile • Potent, and superior selectivity for Chk1 vs. Chk2. • Excellent oral bioavailability in man enables potential broad clinical utility. Differentiated Clinical Strategy • Aggressive clinical development focused on multiple tumor types. • Novel genetically-driven, prospective patient selection strategy designed to demonstrate synthetic lethality. Near-term Data Readouts • Program Update showcasing preclinical and preliminary clinical data planned for February 2018. • Medical conference data anticipated in H2 2018. Significant Commercial Potential • Genetic selection strategy applicable to multiple large market indications. • Additional combination opportunities with other DDR agents (e.g. PARPi) and immuno-oncology agents. 11 SIERRA ONCOLOGY
SRA737: Originates from Renowned Drug Discovery Group with Proven Track Record Discovered and advanced into the clinic by: CRUK/ICR drug discovery track record: Abiraterone (Zytiga) for advanced prostate cancer >$2B ww sales* *2016 Temozolomide for glioblastoma >$1B ww sales* *2008 12 SIERRA ONCOLOGY
SRA737 – Potentially Superior Chk1 Inhibitor Profile SRA737 @ 100nM • SRA737’s potency, selectivity and oral bioavailability could enable a superior efficacy and safety profile. Criterion SRA737 Prexasertib GDC-0575 Stage of Ph1 Ph2 Ph1 development: Presentation: Oral i.v. Oral Biochemical IC 50 : 1.4 nM ~1 nM 2 nM Cmin Chk1 Biochemical IC 50 : SRA737 selectivity: 1850 nM 8 nM unk Chk2 • 15/124 kinases at 10 µM • ERK8 = 100x Selectivity: 1320x ~10x unk • All other kinases >200x Chk1 vs. Chk2 • CDK2 = 2750x • CDK1 = 6750x 13 SIERRA ONCOLOGY
Chk1 Inhibition Induces Synthetic Lethality in Genetically-Mutated Cancer Cells Protein “X" and Chk1 function in parallel compensatory pathways, Protein X Chk1 for example in pathways regulating essential DDR functions required Normal Normal Normal Cell Cell Survives for survival. In normal cells, inactivation of Chk1 Protein X Chk1 is tolerated due to the redundant pathway mediated by Protein “X”. Normal Inhibited Normal Cell Cell Survives In cancer cells, inactivation of Protein “X", by genetic mutation, Chk1 Protein X provides a growth advantage to the tumor, but also increases its Altered Normal dependency on Chk1. Cancer Cell Cell Survives Inactivation of Chk1 by SRA737 in tumor cells harboring a defective Protein “X” is expected to result in Chk1 Protein X simultaneous abrogation of both pathways, leading to synthetic Altered Inhibited Cancer Cell lethality and death of the mutated Cell Death tumor cell. 14 SIERRA ONCOLOGY
Recommend
More recommend
